Dugot Matan, Merzon Eugene, Ashkenazi Shai, Vinker Shlomo, Green Ilan, Golan-Cohen Avivit, Israel Ariel
Adelson School of Medicine, Ariel University, Ariel 40700, Israel.
Leumit Health Services, Tel Aviv 64738, Israel.
Antibiotics (Basel). 2023 Mar 15;12(3):587. doi: 10.3390/antibiotics12030587.
: The susceptibility to SARS-CoV-2 infection is complex and not yet fully elucidated, being related to many variables; these include human microbiome and immune status, which are both affected for a long period by antibiotic use. We therefore aimed to examine the association of previous antibiotic consumption and SARS-CoV-2 infection in a large-scale population-based study with control of known confounders. A matched case-control study was performed utilizing the electronic medical records of a large Health Maintenance Organization. Cases were subjects with confirmed SARS-CoV-2 infection ( = 31,260), matched individually (1:4 ratio) to controls without a positive SARS-CoV-2 test ( = 125,039). The possible association between previous antibiotic use and SARS-CoV-2 infection was determined by comparing antibiotic consumption in the previous 6 and 12 months between the cases and controls. For each antibiotic consumed we calculated the odds ratio (OR) for documented SARS-CoV-2 infection, 95% confidence interval (CI), and -value using univariate and multivariate analyses. The association between previous antibiotic consumption and SARS-CoV-2 infection was complex and bi-directional. In the multivariate analysis, phenoxymethylpenicillin was associated with increased rate of SARS-CoV-2 infection (OR 1.110, 95% CI: 1.036-1.191) while decreased rates were associated with previous consumption of trimethoprim-sulfonamides (OR 0.783, 95% CI: 0.632-0.971) and azithromycin (OR 0.882, 95% CI: 0.829-0.938). Fluroquinolones were associated with decreased rates (OR 0.923, 95% CI: 0.861-0.989) only in the univariate analysis. Previous consumption of other antibiotics had no significant association with SARS-CoV-2 infection. Previous consumption of certain antibiotic agents has an independent significant association with increased or decreased rates of SARS-CoV-2 infection. Plausible mechanisms, that should be further elucidated, are mainly antibiotic effects on the human microbiome and immune modulation.
对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的易感性很复杂,尚未完全阐明,它与许多变量有关;这些变量包括人类微生物群和免疫状态,而抗生素的使用会长期影响这两者。因此,我们旨在通过一项大规模的基于人群的研究,在控制已知混杂因素的情况下,研究既往抗生素使用与SARS-CoV-2感染之间的关联。我们利用一家大型健康维护组织的电子病历进行了一项匹配病例对照研究。病例为确诊SARS-CoV-2感染的受试者(n = 31260),与未进行SARS-CoV-2检测呈阳性的对照个体匹配(1:4比例)(n = 125039)。通过比较病例组和对照组在过去6个月和12个月内的抗生素使用情况,确定既往抗生素使用与SARS-CoV-2感染之间可能存在的关联。对于每种使用的抗生素,我们使用单变量和多变量分析计算记录的SARS-CoV-2感染的比值比(OR)、95%置信区间(CI)和P值。既往抗生素使用与SARS-CoV-2感染之间的关联是复杂且双向的。在多变量分析中,青霉素V与SARS-CoV-2感染率增加相关(OR 1.110,95% CI:1.036 - 1.191),而与既往使用甲氧苄啶 - 磺胺甲恶唑(OR 0.783,95% CI:0.632 - 0.971)和阿奇霉素(OR 0.882,95% CI:0.829 - 0.938)相关的感染率降低。仅在单变量分析中,氟喹诺酮类药物与感染率降低相关(OR 0.923,95% CI:0.861 - 0.989)。既往使用其他抗生素与SARS-CoV-2感染无显著关联。既往使用某些抗生素制剂与SARS-CoV-2感染率的增加或降低存在独立的显著关联。应该进一步阐明的合理机制主要是抗生素对人类微生物群和免疫调节的影响。